Well if we had a proper ADR listing rather than pink sheet I would say biota's share price would be much higher. We can't even price in the cash backing and relenza royalties let alone the pipeline projects.
- Forums
- ASX - By Stock
- BTA
- peramivir failed in a clinical trial
peramivir failed in a clinical trial, page-9
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)